BG
IMUC

BlackRock Group’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

BlackRock Group’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-894
Closed -$92K – 2980
2013
Q3 		$92K Buy
+894
New +$98.2K ﹤0.01% 2619

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

BlackRock Group's IMUC Position: Q4 2013 in Review

BlackRock Group sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2013, closing a stake of 894 shares — an estimated $92K sold.

BlackRock Group first reported a position in IMUC in Q3 2013 and held it in 1 quarter. The position peaked at $92K in Q3 2013. 39 funds tracked by Wall St. Rank hold IMUC as of Q4 2013.

  • BlackRock Group reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2013 after selling out during the quarter.
  • BlackRock Group sold 894 ImmunoCellular Therapeutics, Ltd. shares in Q4 2013, an estimated $92K.
  • BlackRock Group first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2013 and held it in 1 quarter.
  • BlackRock Group's ImmunoCellular Therapeutics, Ltd. position peaked at $92K in Q3 2013.
  • 39 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2013.

Based on BlackRock Group's 13F filing for Q4 2013, filed 12 Feb 2014.